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(VMAT). We present our clinical experience in the first patients (> 6 
months follow-up) to emphasize tolerance to low dose exposure. 
Materials and Methods: We reviewed 198 patients (mean age 55 range 
32-75): 121 were treated for left sided, 72 right sided and 5 for 
bilateral disease. Approximately half of the patients had an indication 
for lymph node irradiation. Patients were treated with an integrated 
boost (SIB) of 50.4/64.4Gy (n=89) or 50/#2Gy(n=32) or with 
42.6/#2.66Gy (START) and 10/#2.5Gy sequential boost (n=66). Sixteen 
patients (> 70 yrs) received 5x (+2x boost) 6.5 Gy weekly. Patients 
were seen weekly and at 1, 3 and 6 month after treatment. Potential 
risk factors for toxicity were tested in 2x2 tables (Fisher´s exact). The 
planning target volume dose was prescribed 95% (maximum< 108%), 
with objectives for respectively, ipsilateral lung (V20Gy<20-30%, 
V5Gy<60-65%), other lung (V5Gy<20%), heart (V10Gy<50%, V35Gy<10%) 
with maximum <35Gy, and contralateral breast (V5Gy<0.5-1%)with 
maximum <10Gy. All dose volume comparisons were adjusted to 
abiological equivalent dose of 2Gy/ fraction.  
Results: During planning VMAT plans were often abandoned (85%) 
mainly because of V5, and alternative IMRT was selected for 
treatment. VMAT plans selected for treatment resulted in higher V10 
in heart (19.7 versus 13.7%), V5 of contralateral breast (0.8 versus 
0.4%) and lung V5 (66.8 versus 63.8). For bilateral, however, VMAT 
resulted in better dose distributions. One bilateral treatment 
consistedof SIB, all others of START, being easier to set up and better 
tolerated. Almost no dermatitis (13% grade 2) or cosmetic 
deterioration was observed. Dry cough was observed in 18% of patients 
and 8 patients) needed medication (pneumonitisgrade 2 RTOG). Plans 
were reviewed and those patients with dry cough showed oftenlung V5 
over 70%. Among other risk factors tested (table 1) lung V5 exposure 
over 70% appeared strongly associated with pneumonitis. After the 
first analysis, we decided to not accept any planning with V5 over 70% 
and no new clinical pneumonitis has appeared since.  
  
Conclusions: IMRT results in less V5 exposure than VMAT planning of 
breast patients. High V5 lung values clearly increase pneumonitis risk. 
More research on low dose exposure is needed to create guidelines for 
dose constraints. Systematic comparison of IMRT to VMAT can 
optimize future planning in breast cancer patients. 
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Purpose/Objective: The development of proton and ion acceleration 
by ultra high intensity lasers for cancer therapy promises the 
realization of compact and economic particle accelerators that can be 
integrated in already existing clinics. For translational research 
towards clinical application the radiobiological consequences of laser 
accelerated and therewith ultra-short pulsed particle beams with high 
pulse dose have to be investigated. After extensive in vitro dose 
response studies with laser driven electron and proton beams, in vivo 
experiments have been performed within the joint research project 
'onCOOPtics' as next translational step. 
Materials and Methods: A mouse tumor model suitable for currently 
available low energy laser protons was developed, tested and 
successfully used. The already in vitro established laser based 
irradiation technology was further developed for the animal model in 
terms of beam transport, beam monitoring, dose delivery and 
dosimetry allowing to apply a prescribed dose to each tumor and to 
determine the absolute dose received. For precise and reproducible 
positioning at the irradiation site a system for mouse fixation, tumor 
positioning and position verification was implemented as described in 
[Schürer et al 2012]. Experiments were carried out at the 30 Terawatt 
Jena Titanium:Sapphire (JeTi) laser system. Laser pulses of 28 fs 
duration were focused into a hydrogen gas jet accelerating electrons 
to energies of up to a few 10 MeV. In vivo tumor irradiation was 
realized for murine sarcoma KHT and human squamous cell carcinoma 
FaDu. Dose sup to 14 Gy were applied at mean dose rates of 1-2 
Gy/min and irradiation induced tumor growth delay was investigated. 
Comparison irradiations were performed at a conventional therapy 
LINAC with the same setup for irradiation and absolute dose 
determination.  
Results: The reliability and stability of all implemented setup 
components and methods were proven by numerous irradiations over a 
period of several months. Dose response curves of tumor growth delay 
were generated for direct comparison of ultra short pulsed laser 
accelerated and conventional continuous electron beam. The ongoing 
data evaluation by now shows no significant difference in RBE for laser 
driven electrons. 
Conclusions: The successful establishment of all technical 
requirements for and the world wide first performance of systematic 
animal studies with laser accelerated electrons mark an important 
step towards the clinical application of laser accelerated particle 
beams. The realization of in vivo studies with laser driven proton 
beams is now feasible.  
The authors thank for the contribution of the Jeti accelerator crew at 
Friedrich-Schiller-University Jena, Ralf Bergmann (HZDR) and for the 
support by the German Ministry of Education and Research (BMBF) 
grant no. 03Z1N511. 
Reference: Schürer et al; Irradiation system for pre-clinical studies 
with laser accelerated electrons; Biomed Tech 2012; 57(Suppl. 1) 
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Purpose/Objective: For treatment planning with carbon ions, the 
local effect model (LEM) is used to predict the relative biological 
effectiveness (RBE) in normal and tumor tissue. Uncertainties in the 
predicted RBEs translate into uncertainty of the prescribed dose, 
which can lead to severe side effects. Therefore, the RBE-models have 
to be validated using experimental data. In a previous study in rat [1], 
the RBE for late reactions of the cervical spinal cord after irradiation 
with carbon ions was measured in the entrance region and at the 
center of a 10 mm spread-out-Bragg-peak (SOBP). A significant 
dependence of the RBE and the fractionation parameter α/β on LET 
was found. Based on this study, we systematically extend this 
database to several intermediate LET-values. 
Materials and Methods: Experiments were performed at the 
experimental beam line at the Heidelberg Heavy Ion Beam Therapy 
Center (HIT). The cervical spinal cord of female Sprague-Dawley rats 
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was irradiated at six different depths of a 6 cm SOBP using a field size 
of 10 x 15 mm2 including the segments C1-C6. The corresponding 
linear energy transfer (LET)-values ranged between 16 and 99 
keV/µm. Irradiations were performed with single and split doses using 
a series of increasing dose levels. Endpoint of the study was the 
occurrence of forelimb paresis grade II within 300 days. Rats with 
paresis grade II were sacrificed, the cervical spinal cord was taken out 
and processed for histological examinations.  
Results: Preliminary analysis of the data shows that with increasing 
LET the RBE-values for single and split doses increase. In general, the 
TD50 (dose at 50 % effect probability) values decrease with increasing 
LET. Compared to the historical data [2] the TD50-values in the 
plateau region are comparable within experimental uncertainties. 
With increasing LET the fractionation ratio (D50 of 2 vs. 1 fraction) 
decreases suggesting an increasing α/β-ratio. 
 The latency time decreases with increasing LET. It is significantly 
shorter for peak irradiation than for plateau irradiation. Latency times 
for peak irradiations were found to be dose dependent while no dose 
dependence was observed for plateau irradiations. 
Conclusions: On the basis of this preliminary analysis the LET effect is 
clearly visible, meaning that high LET irradiations are more effective 
than low LET irradiations. 
 With these studies we extent the database on experimental tolerance 
doses and RBE-values of the rat cervical spinal cord. The data allow to 
study and assess accuracy and limitations of RBE-models by comparing 
measured and calculated RBE-values. Further experiments with six 
fractions will be performed, which will allow a more robust 
determination of α/β-ratio as a function of LET. To elucidate the 
mechanisms of the radiation damage, an additional MRI and histology-
based longitudinal study is ongoing.  
References 
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Purpose/Objective: Urethral stricture is one of the known 
complications in the treatment for prostate cancer, regardless the 
particular therapeutic modality. We reviewed our experience in 
patients treated with high dose rate (HDR) brachytherapy for prostate 
cancer, identifying incidence, timing, and outcomes in those who 
developed urethral stricture after the procedure. We also attempted 
to seek a solution in treatment technique and planning to prevent 
such occurrence. 
Materials and Methods: Since 1997, 448 patients had undergone HDR 
brachytherapy for clinically localized prostate cancer in our 
institution. Over 95% of our patients had intermediate or high risk 
tumor and practically all patients received neo-adjuvant hormone 
therapy. The HDR protocol typically called for 3 treatment sessions 
with one overnight stay. A single radioactive iridium-192 source was 
used with a nominal activity of 370 GBq. The prescribed dose of 6 Gy 
per session covered at least 95% of the prostate volume (PTV). All 
patients received supplementary external beam radiation therapy 
following completion of the brachytherapy procedure, and external 
beam dose ranged from 45 Gy to 50.4 Gy (median 50 Gy) using 
conventional fractionation schemes. For the past two years, the 
brachytherapy regimen was changed to a single fraction of 13 Gy, thus 
all patients could be treated on an outpatient basis. All urethral 
strictures were diagnosed cystoscopically. Patient demographics, 
operative, and postoperative data were reviewed. 
Results: Overall survival rate of the entire cohort of our patients was 
98.6%, with a mean follow-up of 55 months. Two patients died from 
metastasis and 2 other patients died from unrelated causes. Twenty-
two patients (5%) have developed urethral strictures to-date. The 
median time between radiation therapy and the diagnosis of urethral 
stricture was 4 years (range 1-8 years), with nearly all strictures 
located in the bulbomembranous urethra. At last follow-up, 2 of the 
22 patients had a patent urethra. The remaining 20 patients did not 
have a stable patent urethra. Nine (41%) of these patients required a 
urethral dilation schedule, and 3 patients (14%) needed either 
suprapubic tube or urethral catheter drainage. Five patients (23%) 
required multiple endoscopic procedures or dilations, while 3 patients 
(14%) required dilation at last follow-up.  
Conclusions: Risk of urethral stricture from HDR brachytherapy for 
clinically localized prostate cancer appears real. Although incidence 
of radiation induced urethral stricture remains relatively low, it could 
result in significant morbidity for the patients. With improved 
catheter placement technique and meticulous treatment planning 
accomplishing 'donut' dosimetry presently, we could expect reduced 
incidence of this complication after HDR brachytherapy for prostate 
cancer. 
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Purpose/Objective: Inverse treatment planning requires constraints 
for adequate dose coverage of the prostate and limitation of the dose 
to the organs at risk. The purpose of this study was to investigate if 
there is a relation between the dose to the different sub-segments of 
the lower urinary tract and enhanced lower urinary tract symptoms 
(LUTS) after low dose rate brachytherapy with I-125 seeds, and if 
there is, to determine a dose constraint for treatment planning 
purposes. 
Materials and Methods:  
  
his study involved 225 patients treated for prostate cancer with I-125 
seeds with a prescribed dose of 145 Gy. The patients filled in an 
International Prostate Symptom Score (IPSS) questionnaire before 
(baseline) and 1 week, 6 weeks and 3 months after the implantation 
of the seeds. These post-implant scores cover the time period when 
LUTS levels are expected to be maximal. On post-implant fused CT-
TRUS images the prostate, the urethra, the bladder wall, the bladder 
neck and the external sphincter were delineated (see figure) and 
cumulative dose volume histograms (CDVHs) were determined. The 
bladder neck was defined by the urethral orifice connecting the 
bladder and the prostatic urethra plus a 5 mm margin in all directions. 
The external sphincter was defined by that part of the urethra that 
connects the prostatic and the membranous trajectory plus a 5 mm 
margin in all directions. The endpoint was the mean IPSS during the 
first 3 months after the treatment. For binary analysis the patients 
were stratified in a group with enhanced LUTS (mean post-implant 
IPSS ≥12 and mean increase over baseline IPSS ≥6, or catheter depen-
dency) and a group with non-enhanced LUTS. 
Results: Multivariate linear regression analysis revealed that the dose 
to 0.5 cm3 of the bladder neck 'D0.5cc-blne' (p=0.002), the prostate 
volume prior to treatment 'Vpr -0' (p=0.005) and the baseline IPSS 
(p<0.001) were independently correlated with the mean IPSS. When 
'high' is defined as ≥175 Gy and ≥42 cm3 for D0.5cc-blne and Vpr -0, 
respectively, and 'low' as < than these values, 68% of the patients with 
a high D0.5cc-blne and a high Vpr -0 suffered from enhanced LUTS, 
against 31%, 36% and 23% for the combinations high-low, low-high and 
low-low of these parameters, respectively (p<0.0001).  
Conclusions: Prostate volume and dose to the bladder neck are 
correlated with post-implant IPSS. A combination of a large prostate 
and a high dose to the bladder neck is highly predictive for enhanced 
early LUTS. To minimize the incidence of enhanced LUTS, D0.5cc-blne 
should be constrained to a maximum value of 175 Gy during the 
treatment planning process. 
 
 
 
 
 
 
